Woodline Partners LP Chinook Therapeutics, Inc. Transaction History

Woodline Partners LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.66 - $38.58 $11.5 Million - $23.8 Million	617,907 New	617,907 $23.7 Million
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $3.11 Million - $4.56 Million	-166,821 Reduced 53.92%	142,563 $3.74 Million
Q3 2022 Nov 14, 2022	SELL	$17.51 - $23.37 $1.6 Million - $2.14 Million	-91,639 Reduced 22.85%	309,384 $6.08 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $5.05 Million - $7.54 Million	401,023 New	401,023 $7.01 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.